# A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis

> **NCT06975748** · PHASE2 · RECRUITING · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Neurotrophic Keratitis

## Interventions

- **DRUG:** STSP-0902 ophthalmic solution
- **DRUG:** STSP-0902 ophthalmic solution
- **DRUG:** STSP-0902 Placebo

## Key facts

- **NCT ID:** NCT06975748
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2026-04
- **Final completion:** 2026-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975748, "A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06975748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*